if you’ve only researched Clinuvel for two days you’ll probably need to study a little bit longer. EPP is only the first orphan indication off the rank. With 40% yoy growth coupled with application for marketing to be submitted in Japan and Australia closely followed by XP and variagte porphyria indication extensions I don’t see $75mil sustained revenue being a problem. Add in vitiligo and the numbers are off the charts. Add in all dermatoses including Hailey-Hailey disease reaching large population numbers with reduced per unit price and we will have a monolithic company...
if you’ve only researched Clinuvel for two days you’ll probably...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.430(2.87%) |
Mkt cap ! $771.0M | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.39 | $14.83 | $2.149M | 141.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 590 | $15.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.41 | 1079 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |